In June ----, AstraZeneca entered into a commercialisation agreement with Aspen Global (Aspen Pharmacare) for rights to AstraZeneca s global anaesthetics portfolio outside the US. Under the terms of the agreement, which covers seven established medicines, Aspen will acquire the commercialisation rights for an up-front consideration of USD---mn, milestone and royalty payments. ...In June ----, AstraZeneca entered into a commercialisation agreement with Aspen Global (Aspen Pharmacare) for rights to AstraZeneca s global anaesthetics portfolio outside the US. In addition, GlaxoSmithKline and Aspen have terminated their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK s remaining thrombosis business in certain retained markets. In April ----, Johnson & Johnson officially launched its global public health (GPH) strategy at the opening of its on-the-ground GPH operations in Cape Town, South Africa. Through this global strategy, Johnson & Johnson will mobilise its global public health capabilities and resources behind a unified, multidisciplinary effort. The company s GPH strategy will include early stage disease-specific research, product development, manufacturing and distribution, and education and training resources through its philanthropic efforts.
...Rising competition from low-cost generic drug producers. State organisations will be compelled to buy some drugs exclusively from domestic suppliers. ...Modernisation costs to potentially prohibit harmonisation of domestic regulation with international norms. Price restrictions and proposed benchmarking are likely to lead to a reduction in foreign investment and even result in some companies exiting the market. Rising private health costs threatening to put private health insurance further out of reach of the majority of the population. ...Rising private health costs threatening to put private health insurance further out of reach of the majority of the population. Rand depreciation to raise cost of imports and worsen profitability of overseas manufacturers.
...In September ----, AstraZeneca has completed its commercialisation agreement with Aspen Global (Aspen Pharmacare) for rights to AstraZeneca s global anaesthetics portfolio outside of the US. The agreement covers seven established medicines: Diprivan (propofol), EMLA and five local anaesthetics with combined yearly revenue of USD---mn. ...
